

Special Issue

Psychotropic Drug Therapies and Clinical Considerations in Modern Practice, Volume II

Message from the Guest Editors

The rate of progress in psychotropic drug development has been rapid over the last 15 years. There have also been unprecedented rises in expenditure on prescription medications in general and on psychotropic drugs in particular. Psychotropic drugs play a more central role in therapy. They are also closely watched by health insurers, state budget makers, and ordinary people. Modern psychopharmacology has provided therapeutic advantages that have completely revolutionized modern psychiatry. It has also had a significant effect on nosology and psychological disease theories, on hypotheses for psychiatric study, as well as on the preparation of mental health practitioners and the organization of contemporary mental health services. Keywords

- opioids
- antidepressants
- ADHD
- PTSD

Guest Editors

Dr. Alan David Kaye

Department of Anesthesiology, Louisiana State University, Shreveport, LA, USA

Dr. Elyse M. Cornett

Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA, USA

Deadline for manuscript submissions

closed (28 February 2024)



Neurology International

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.8
Indexed in PubMed



mdpi.com/si/168293

Neurology International
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
neurolint@mdpi.com

[mdpi.com/journal/
neurolint](https://mdpi.com/journal/neurolint)





Neurology International

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.8
Indexed in PubMed



[mdpi.com/journal/
neurolint](https://mdpi.com/journal/neurolint)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Junji Yamauchi

1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
2. Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Clinical Neurology)